Some recent advances in leukotriene research

Advances in Experimental Medicine and Biology

Volumn 433, Issue , 1997, Pages 1-7

  Samuelsson, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; EPOXIDE HYDROLASE; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PEPTIDOLEUKOTRIENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR;

ARTICLE; ASTHMA; ENZYME ACTIVITY; EPOXIDATION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; XENOBIOTIC METABOLISM;

EID: 0031392386     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-1810-9_1     Document Type: Article

References (47)

1. B. Samuelsson, Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation, Science, 220:568-575, (1983).
2. B. Samuelsson, S.-E. Dahlén, J.-Å. Lindgren, C.A. Rouzer, and C.N. Serhan, Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects, Science, 237:1171-1176, (1987).
3. 4, Proc. Natl Acad. Sci. USA, 80:1712-1716, (1983).
4. R.A. Coleman, R.M. Eglen, R.L. Jones, S. Narumiya, T. Shimizu, W.L. Smith, S.E. Dahlén, J.M. Drazen, P.J. Gardiner, W.T. Jackson, T.R. Jones, R.D. Krell, and S. Nicosia, Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature, in: Adv. Prostaglandin Thromboxane Leukotriene Res, 23:283-285, (1995).
5. P.R. Devchand, H. Keller, J.M. Peters, M. Vazquez, F.J. Gonzalez, and W. Wahli, The ppar-alpha-leukotriene b-4 pathway to inflammation control, Nature, 384:39-43, 1996.
6. 4 in inflammation, Immunology, 10:1-12, (1990).
7. 4 augments human natural killer cytotoxic cell activity, Biochem. Biophys. Res. Commun., 113: 531-537, (1983).
8. + lymphocyte phenotype and immunoregulatory functions, J. Immunol., 135:1357-1360, (1985).
9. M. Rola-Pleszczynski and I. Lemaire, Leukotrienes augment interleukin-1 production by human monocytes, J. Immunol., 135:3958-3961, (1985).
10. 4 in human lymphocyte cultures, Prostagl. Leukotr. Med, 23:207-210, (1986).
11. 4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes, Biochem. J., 282:625-629, (1992).
12. 4 enhances activation, proliferation, and differentiation of human B lymphocytes, J. Immunol., 143: 1996-2000, (1989).
13. 4, and histamine in asthmatics, Am. Rev. Respir. Dis, 146:96-103, (1992).
14. W.R. Henderson, New modalities for the pharmacotherapy of asthma - leukotriene inhibitors and antagonists, Immunology & Allergy Clinics of North America, 16:797 ff., (1996).
15. J.M. Drazen, Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma, Pharmacotherapy, 17:S22-S30, (1997).
16. J.S. Larsen and S.K. Jackson, Antileukotriene therapy asthma, American Journal of Health-System Pharmacy, 53:2821-2830, (1996).
17. P.M. Obyrne, Exercise-induced bronchoconstriction - elucidating the roles of leukotrienes and prostaglandins, Pharmacotherapy, 17:S 31-S 38, (1997).
18. J.C. Boyington, B.J. Gaffney, and L.M. Amzel, The three-dimensional structure of an arachidonic acid 15-lipoxygenase, Science, 260:1482-1486, (1993).
19. W. Minor, J. Steczko, J.T. Bolin, Z. Otwinowski, and B. Axelrod, Crystallographic determination of the active site iron and its ligands in soybean lipoxygenase L1, Biochemistry, 32:6320-6323, (1993).
20. T. Hammarberg, Y.-Y. Zhang, B. Lind, O. Rådmark, and B. Samuelsson, Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase, European J Biochem, 230:401-407, (1995).
21. C.D. Funk, S. Hoshiko, T. Matsumoto, O. Rådmark, and B. Samuelsson, Characterization of the human 5-lipoxygenase gene, Proc. Natl. Acad. Sci. USA, 86: 2587-2591, (1989).
22. K.H. In, K. Asano, D. Beier, J. Grobholz, P.W. Finn, E.K. Silverman, E.S. Silverman, T. Collins, A.R. Fischer, T.P. Keith, K. Serino, S.W. Kim, G.T. Desanctis, C. Yandava, A. Pillari, P. Rubin, J. Kemp, E. Israel, W. Busse, D. Ledford, J.J. Murray, A. Segal, D. Tinkleman, and J.M. Drazen, Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription, Journal of Clinical Investigation, 99:1130-1137, (1997).
23. D. Steinhilber, M. Brungs, O. Werz, I. Wiesenberg, C. Danielsson, J.-P. Kahlen, S. Nayeri, M. Schräder, and C. Carlberg, The Nuclear Receptor for Melatonin Represses 5-Lipoxygenase Gene Expression in Human B Lymphocytes, J . Biol. Chem, 270:7037-7040, (1995).
24. D. Steinhilber, O. Rådmark, and B. Samuelsson, Transforming growth factor-β upregulates 5-lipoxygenase activity during myeloid cell maturation, Proc. Natl. Acad. Sci. USA:in press, (1993).
25. 3., Proc. Natl. Acad. Sci., 92:107-111, (1995).
26. A.W. Ford-Hutchinson, 5-Lipoxygenase activation in psoriasis: a dead issue?, Skin Pharmacol, 6:292-297, (1993).
27. U. Janssen-Timmen, PJ. Vickers, U. Wittig, W.D. Lehmann, H.-J. Stark, N.E. Fusenig, T. Rosenbach, O. Rådmark, B. Samuelsson, and A.J.R. Habenicht, Expression of 5-lipoxygenase in differentiating human skin keratinocytes., Proc. Natl. Acad. Sci., 92:6966-6970, (1995).
28. T.G. Brock, R. Paine, III, and M. Peters-Golden, Localization of 5-lipoxygenase to the nucleus of unstimulated rat bosophilic leukemia cells, J. Biol. Chem, 269: 22059-22066, (1994).
29. 2 to the nuclear fraction upon macrophage activation., Biochem. Biophys. Res. Commun., 196:147-153, (1993).
30. J.W. Woods, M. Coffey, T. Brock, I. Singer, and M. Peters-Golden, 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest., 95:2035-2040, (1995).
31. X.-S. Chen, T.A. Naumann, U. Kurre, N.A. Jenkins, and N.G. Copeland, C.D, J. Biol. Chem, 270:17993-17999, (1995).
32. J.W. Woods, J.F. Evans, D. Ethier, S. Scott, P.J. Vickers, L. Hearn, J. A. Heibein, S. Charleson, and I.I. Singer, 5-lipoxygenase and 5-lipoxygenase activating protein are localized in the nuclear envelope of activated human leukocytes., J. Exp. Med., 178:1935-1946, (1993).
33. T.G. Brock, R.W. McNish, and M. Peters-Golden, J. Biol. Chem., 270:21652-21658, (1995).
34. T.G. Brock, R.W. McNish, M.B. Bailie, and M. Peters-Golden, Rapid Import of Cytosolic 5-Lipoxygenase into the Nucleus of Neutrophils after in Vivo Recruit-ment and in Vitro Adherence, J. Biol Chem, 272:8276-8280, (1997).
35. R.A. Lepley and F.A. Fitzpatrick, 5-Lipoxygenase Contains a Functional Src Homology 3-binding Motif that Interacts with the Src Homology 3 Domain of GrB2 and Cytoskeletal Proteins, J. Biol. Chem, 269:24163-24168, (1994).
36. R.A. Lepley, T. Muskardin, and F.A. Fitzpatrick, "Tyrosine Kinase Activity Modulates Catalysis and Translocation of Cellular 5-Lipoxygenase, J. Biol. Chem, 271:6179-6184, (1996).
37. 4 hydrolase: An epoxide hydrolase with peptidase activity, Biochem. Biophys. Res. Commun., 173:431-437, (1990).
38. 4 hydrolase is a zinc-containing aminopeptidase, Biochem. Biophys. Res. Commun., 173:620-626, (1990).
39. 4 hydrolase: structural and functional properties of the active center, J. Lipid. Med., 6:1-13, (1993).
40. 4: Purification and characterization of a novel epoxide hydrolase from human erythrocytes, J. Biol. Chem., 260:12832-12837, (1985).
41. 4 hydrolase, J. Biol. Chem., 260:10966-10970, (1985).
42. 4, Biochim. Biophys. Acta, 794:56-64, (1984).
43. 4 hydrolase: Mapping of a henicosapeptide involved in mechanism-based inactivation, Proc. Natl. Acad. Sci. USA, 92: 8383-8387, (1995).
44. 4 hydrolase: Protection from mechanism-based inactivation by mutation of tyrosine-378, Proc. Natl. Acad. Sci. USA, 93:5931-5935, (1996).
45. 4, J. Biol. Chem, 271:24345-24348, (1996).
46. 4 hydrolase, Eur. J. Biochem, 231:528-534, (1995).
47. 4 into 5S,6S-DHETE, implications for the epoxide hydrolase mechanism, J. Biol. Chem., subm. for publ. ( 1997).